Van ECK Associates Corp Has $29.67 Million Stock Position in Sanofi (NASDAQ:SNY)

Van ECK Associates Corp trimmed its position in shares of Sanofi (NASDAQ:SNY) by 0.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 561,036 shares of the company’s stock after selling 993 shares during the quarter. Van ECK Associates Corp’s holdings in Sanofi were worth $29,673,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently bought and sold shares of the business. GFS Advisors LLC grew its stake in shares of Sanofi by 1,017.9% during the third quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock worth $738,000 after purchasing an additional 11,655 shares during the period. Farther Finance Advisors LLC grew its stake in shares of Sanofi by 12.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,861 shares of the company’s stock worth $165,000 after acquiring an additional 309 shares in the last quarter. Weatherly Asset Management L. P. increased its position in shares of Sanofi by 12.1% in the third quarter. Weatherly Asset Management L. P. now owns 8,507 shares of the company’s stock valued at $490,000 after acquiring an additional 916 shares during the last quarter. Principal Securities Inc. raised its position in Sanofi by 6.0% during the third quarter. Principal Securities Inc. now owns 45,050 shares of the company’s stock worth $2,596,000 after acquiring an additional 2,555 shares in the last quarter. Finally, US Bancorp DE lifted its stake in Sanofi by 8.6% in the 3rd quarter. US Bancorp DE now owns 111,405 shares of the company’s stock valued at $6,420,000 after purchasing an additional 8,813 shares during the last quarter. Institutional investors own 10.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on SNY. Argus raised their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. StockNews.com raised shares of Sanofi from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $57.50.

Sanofi Price Performance

SNY opened at $52.95 on Tuesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm’s fifty day moving average price is $55.85 and its two-hundred day moving average price is $52.10. Sanofi has a 1 year low of $45.00 and a 1 year high of $58.97. The company has a market capitalization of $134.38 billion, a price-to-earnings ratio of 27.02, a P/E/G ratio of 1.35 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. The firm had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company’s revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.55 EPS. As a group, analysts anticipate that Sanofi will post 4.27 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.